New hope for lung cancer patients: lower-dose targeted drug trial launched
NCT ID NCT05037331
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times
Summary
This study tests a lower dose of the targeted drug osimertinib in 58 adults with advanced EGFR-positive non-small cell lung cancer. The goal is to see if the lower dose is safer while still controlling the disease. Participants take the drug every other day, and researchers monitor side effects, tumor response, and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
National University Hospital
RECRUITINGSingapore, Singapore
Contact
Contact
Conditions
Explore the condition pages connected to this study.